List of Chantix drug patents
Chantix is owned by Pf Prism Cv.
Chantix contains Varenicline Tartrate.
Chantix has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Chantix are:
- US6890927*PED
- US7265119*PED
- US6890927
- US7265119
Chantix was authorised for market use on 10 May, 2006.
Chantix is available in tablet;oral dosage forms.
Chantix can be used as aid to smoking cessation.
The generics of Chantix are possible to be released after 03 February, 2023.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6890927 | PF PRISM CV | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
May, 2022
(9 months ago) | |
| US7265119 | PF PRISM CV | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Aug, 2022
(6 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6890927
(Pediatric) | PF PRISM CV | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Nov, 2022
(3 months ago) | |
|
US7265119
(Pediatric) | PF PRISM CV | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Feb, 2023
(3 days ago) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Feb 22, 2022 |
| Pediatric Exclusivity (PED) | Aug 22, 2022 |
Drugs and Companies using VARENICLINE TARTRATE ingredient
Market Authorisation Date: 10 May, 2006
Treatment: Aid to smoking cessation
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic